Juan D Cañete Selected Research

Palindromic rheumatism

12/2021	Palindromic rheumatism: Evidence of four subtypes of palindromic-like arthritis based in either MEFV or rheumatoid factor/ACPA status.
1/2020	Anti-carbamylated protein antibody isotype pattern differs between palindromic rheumatism and rheumatoid arthritis.
1/2017	Differing specificities and isotypes of anti-citrullinated peptide/protein antibodies in palindromic rheumatism and rheumatoid arthritis.
8/2014	Is there subclinical synovitis in patients with palindromic rheumatism in the intercritical period? a clinical and ultrasonographic study according to anticitrullinated protein antibody status.
10/2012	Palindromic rheumatism with positive anticitrullinated peptide/protein antibodies is not synonymous with rheumatoid arthritis. A longterm followup study.
8/2007	An unexpectedly high frequency of MEFV mutations in patients with anti-citrullinated protein antibody-negative palindromic rheumatism.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Juan D Cañete Research Topics

Disease

57	Rheumatoid Arthritis 05/2022 - 03/2004
35	Psoriatic Arthritis 11/2021 - 05/2004
15	Inflammation (Inflammations) 10/2021 - 07/2008
11	Arthritis (Polyarthritis) 01/2022 - 05/2004
9	Synovitis 01/2022 - 05/2004
7	Infections 01/2020 - 01/2013
6	Palindromic rheumatism 12/2021 - 08/2007
6	Rheumatic Diseases (Rheumatism) 01/2021 - 04/2011
6	Ankylosing Spondylitis 11/2020 - 08/2012
6	Psoriasis (Pustulosis Palmaris et Plantaris) 10/2020 - 01/2016
5	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2021 - 05/2008
4	Pain (Aches) 11/2021 - 07/2014
4	Necrosis 01/2021 - 06/2007
4	Neoplasms (Cancer) 01/2020 - 12/2013
4	Osteoarthritis 03/2016 - 06/2003
3	Fatigue 12/2020 - 07/2016
2	Communicable Diseases (Infectious Diseases) 12/2021 - 01/2020
2	Joint Diseases (Joint Disease) 11/2020 - 01/2016
2	Injection Site Reaction 01/2020 - 06/2015
2	Uveitis 01/2020 - 03/2018
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2020 - 01/2016
2	Crohn Disease (Crohn's Disease) 06/2017 - 01/2016
2	Ulcerative Colitis 06/2017 - 01/2016
2	Hyperplasia 09/2011 - 08/2006
1	Fever (Fevers) 12/2021
1	Pericarditis 12/2021
1	Abdominal Pain (Pain, Abdominal) 12/2021
1	Asthma (Bronchial Asthma) 01/2021
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 06/2020
1	Obesity 06/2020
1	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2020
1	Multiple Sclerosis 01/2020
1	Non-alcoholic Fatty Liver Disease 01/2020
1	Immune System Diseases (Immune Disorders) 01/2020
1	Dysbiosis 01/2020
1	Wounds and Injuries (Trauma) 01/2019
1	type 2C Congenital disorder of glycosylation 01/2019
1	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 12/2018

Drug/Important Bio-Agent (IBA)

16	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2014
12	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2016 - 03/2004
11	CytokinesIBA 11/2019 - 07/2008
10	Biological ProductsIBA 01/2021 - 01/2005
10	Proteins (Proteins, Gene)FDA Link 01/2020 - 08/2006
9	Tumor Necrosis Factor InhibitorsIBA 01/2019 - 08/2012
8	AutoantibodiesIBA 05/2022 - 06/2007
8	Infliximab (Remicade)FDA Link 01/2016 - 03/2004
7	Etanercept (Enbrel)FDA Link 01/2016 - 03/2004
6	AntibodiesIBA 01/2022 - 01/2009
6	Antirheumatic Agents (DMARD)IBA 01/2021 - 01/2017
6	Peptides (Polypeptides)IBA 01/2020 - 01/2009
5	Leukocyte L1 Antigen Complex (Calgranulin)IBA 12/2018 - 12/2015
5	Adalimumab (Humira)FDA Link 01/2016 - 08/2012
4	C-Reactive ProteinIBA 01/2022 - 01/2016
4	InterleukinsIBA 01/2020 - 03/2012
4	Interleukin-17 (Interleukin 17)IBA 01/2020 - 07/2015
3	Interleukin-6 (Interleukin 6)IBA 01/2022 - 09/2015
3	Rheumatoid FactorIBA 12/2021 - 09/2009
3	ametantrone (HAQ)IBA 11/2021 - 12/2020
3	Immunomodulating AgentsIBA 01/2021 - 01/2016
3	Methotrexate (Mexate)FDA LinkGeneric 07/2018 - 05/2004
3	Acute-Phase Proteins (Acute-Phase Protein)IBA 01/2016 - 12/2015
2	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2021 - 09/2015
2	RNA (Ribonucleic Acid)IBA 01/2021 - 01/2021
2	tocilizumab (atlizumab)FDA Link 01/2021 - 12/2015
2	EpitopesIBA 01/2017 - 09/2009
2	LigandsIBA 07/2015 - 12/2012
2	DNA (Deoxyribonucleic Acid)IBA 11/2014 - 05/2013
2	acetyl 4-aminosalicylic acidIBA 04/2011 - 05/2008
2	ChemokinesIBA 07/2008 - 06/2007
2	Anti-Citrullinated Protein AntibodiesIBA 05/2008 - 08/2007
1	Janus Kinase InhibitorsIBA 01/2022
1	Colchicine FDA LinkGeneric 12/2021
1	Genetic Markers (Genetic Marker)IBA 10/2021
1	Small Cytoplasmic RNAIBA 01/2021
1	mepolizumabIBA 01/2021
1	Rituximab (Mabthera)FDA Link 01/2021
1	OvalbuminIBA 01/2021
1	Interleukin-6 InhibitorsIBA 10/2020
1	Prostaglandins AIBA 06/2020
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2020
1	Indicators and Reagents (Reagents)IBA 01/2020
1	CannabinoidsIBA 01/2020
1	ixekizumabIBA 01/2020
1	Butyrates (Butyrate)IBA 01/2020
1	Anti-Idiotypic AntibodiesIBA 01/2020
1	larazotide acetateIBA 01/2020
1	zonulinIBA 01/2020
1	InterferonsIBA 11/2019
1	A-Form DNA (A-DNA)IBA 11/2019
1	Arginine (L-Arginine)FDA Link 01/2019
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2019
1	fos-related antigen 1IBA 01/2019
1	GlycosaminoglycansIBA 01/2019
1	Transcription Factors (Transcription Factor)IBA 01/2019
1	ArginaseIBA 01/2019
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 07/2018
1	Sulfasalazine (Azulfidine)FDA LinkGeneric 03/2018
1	Leflunomide (Arava)FDA LinkGeneric 03/2018

Therapy/Procedure

22	Therapeutics 01/2022 - 05/2004
11	Biological Therapy 10/2020 - 09/2011